MSAM
SLXN

Moloney Securities Asset Management’s Silexion Therapeutics SLXN Stock Holding History

Moloney Securities Asset Management’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133
Closed -$16.2K – 534
2025
Q2 		$16.2K Buy
+133
New +$18K ﹤0.01% 484

Other funds holding SLXN

MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Moloney Securities Asset Management's SLXN Position: Q3 2025 in Review

Moloney Securities Asset Management sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 133 shares — an estimated $16.2K sold.

Moloney Securities Asset Management first reported a position in SLXN in Q2 2025 and held it in 1 quarter. The position peaked at $16.2K in Q2 2025. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

  • Moloney Securities Asset Management reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Moloney Securities Asset Management sold 133 Silexion Therapeutics shares in Q3 2025, an estimated $16.2K.
  • Moloney Securities Asset Management first reported a position in Silexion Therapeutics in Q2 2025 and held it in 1 quarter.
  • Moloney Securities Asset Management's Silexion Therapeutics position peaked at $16.2K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.